Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bullous pemphigoid].

Julie de Quatrebarbes1, Pascal Joly

  • 1Clinique dermatologique, hôpital Charles Nicolle, 76000 Rouen. Julie.de-quatrebarbes@chu-rouen.fr

La Revue Du Praticien
|September 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.

The British journal of dermatology·2026
Same author

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same author

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

The Journal of investigative dermatology·2026
Same author

Tocilizumab for severe and refractory mucous membrane pemphigoid.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Incidence and Mortality of Mucous Membrane Pemphigoid in France.

The British journal of dermatology·2026
Same author

Baricitinib and low-dose prednisone for very severe alopecia areata: A retrospective case series.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Bullous pemphigoid (BP) is a common autoimmune blistering skin disease in the elderly. Current European treatments focus on topical steroids like clobetasol propionate for managing BP symptoms.

Area of Science:

  • Dermatology
  • Immunology
  • Pathology

Background:

  • Bullous pemphigoid (BP) is the most common autoimmune blistering disease affecting the elderly.
  • It involves antibodies targeting hemidesmosomal proteins BPAG1 and BPAG2 at the dermal-epidermal junction.
  • Clinical presentation includes pruritus and tense blisters, typically on limbs and trunk, healing without scarring.

Purpose of the Study:

  • To summarize the key aspects of bullous pemphigoid.
  • To outline diagnostic criteria and common treatments.

Main Methods:

  • Review of clinical features, histological findings, and immunofluorescence results in BP.
  • Description of current therapeutic approaches in Europe.

Main Results:

Related Experiment Videos

  • Histopathology reveals subepidermal blisters with eosinophils.
  • Direct immunofluorescence shows linear IgG/C3 deposits at the dermal-epidermal junction.
  • Topical corticosteroid therapy, such as clobetasol propionate, is a primary treatment in Europe.

Conclusions:

  • Bullous pemphigoid is characterized by specific autoantibodies and distinct clinical and histological findings.
  • Effective management in Europe relies on topical steroid application.